Jeffrey Sevigny Net Worth

Jeffrey Sevigny biography

Dr. Jeffrey Sevigny M.D. serves as Chief Medical Officer of the Company. Prior to joining us, he served as Vice President and Global Head of Translational Medicine Neuroscience at Roche from January 2016 to March 2018. Prior to Roche, he was Senior Director of Clinical Development at Biogen Inc., a multinational biotechnology company, from September 2010 to January 2016. Previously, he served as Principal Medical Scientific Expert of Neuroscience at Novartis AG, a multinational pharmaceutical company, and as Associate Director of Neuroscience at Merck. Dr. Sevigny has also held academic appointments as Assistant Professor of Neurology at Albert Einstein School of Medicine and Assistant Professor of Clinical Neurology at Columbia University College of Physicians and Surgeons. Dr. Sevigny received an M.D. from Tufts University School of Medicine and an A.B. in biochemistry from Bowdoin College. He completed a neurology residency at the Neurological Institute of New York at Columbia University Medical Center and a fellowship in Aging & Dementia and Neuro-Epidemiology at Sergievsky Center at Columbia University and Columbia University Mailman School of Public Health.

What is the salary of Jeffrey Sevigny?

As the Chief Medical Officer of Prevail Therapeutics Inc, the total compensation of Jeffrey Sevigny at Prevail Therapeutics Inc is $1,462,200. There are 1 executives at Prevail Therapeutics Inc getting paid more, with Asa Abeliovich having the highest compensation of $2,861,680.

How old is Jeffrey Sevigny?

Jeffrey Sevigny is 51, he's been the Chief Medical Officer of Prevail Therapeutics Inc since 2018. There are 8 older and 4 younger executives at Prevail Therapeutics Inc. The oldest executive at Prevail Therapeutics Inc is Franz Hefti, 72, who is the Chief Development Officer.

What's Jeffrey Sevigny's mailing address?

Jeffrey's mailing address filed with the SEC is C/O PREVAIL THERAPEUTICS INC., 430 EAST 29TH STREET, SUITE 1520, NEW YORK, NY, 10016.

Insiders trading at Prevail Therapeutics Inc

Over the last 5 years, insiders at Prevail Therapeutics Inc have traded over $0 worth of Prevail Therapeutics Inc stock and bought 36,931,845 units worth $816,407,705 . The most active insiders traders include Acquisition Corp Eli Lilly ..., Peter A. Thompson, eAdvisors Llc Orbi Med Capit.... On average, Prevail Therapeutics Inc executives and independent directors trade stock every 96 days with the average trade being worth of $138,767,762. The most recent stock trade was executed by Acquisition Corp Eli Lilly ... on 22 January 2021, trading 34,284,789 units of PRVL stock currently worth $771,407,753.

What does Prevail Therapeutics Inc do?

Prevail Therapeutics Inc executives and stock owners

Prevail Therapeutics Inc executives and other stock owners filed with the SEC include:

• Asa Abeliovich,
  President, Chief Executive Officer, Director
• Jeffrey Sevigny,
  Chief Medical Officer
• Yong Dai,
  Chief Technology Officer
• Franz Hefti,
  Chief Development Officer
• Francois Nader,
  Independent Chairman of the Board
• Timothy Adams,
  Independent Director
• Morgan Sheng,
  Independent Director
• Ran Nussbaum,
  Independent Director
• Carl Gordon,
  Director
• Peter Thompson,
  Independent Director
• William Carson,
  Director
• Emily Minkow,
  Chief Business Officer
• Kira Schwartz,
  General Counsel
• Brett Kaplan,
  Chief Financial Officer
• Advisors Llc Orbi Med Capit...,
  
• Acquisition Corp Eli Lilly ...,